US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

CareDx, Inc. - Common Stock (NQ:CDNA)

63.12 -0.55 (-0.86%)
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals ↗
Via Chartmill
CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Case ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Meets Minervini Trend Template with High-Growth Momentum ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Screens Well on High Growth Momentum and Breakout Setup ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Combines Strong Growth With a Bullish Technical Setup ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentals ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Passes Both the Minervini Trend Template and High Growth Momentum Tests ↗
Via Chartmill
CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup ↗
Via Chartmill
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
News headline image
Why CareDx Stock Jumped Today ↗
The diagnostics leader is accelerating the trend toward precision medicine. 
Via The Motley Fool
News headline image
CareDx Q2 Earnings Call Highlights ↗
CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began... 
Via MarketBeat
Topics Earnings
News headline image
CareDx Announces Second Quarter 2026 Financial Results
From CareDx, Inc.
Via Business Wire
What's going on in today's session ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
From CareDx, Inc.
Via Business Wire
News headline image
CareDx's CEO Sells 17K Shares ↗
CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans ↗
CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted... 
Via MarketBeat
Topics Intellectual Property
News headline image
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies ↗
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing... 
Via MarketBeat
News headline image
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Dismissal of 2021 Qui Tam Suit
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
News headline image
CareDx (CDNA) Q1 2026 Earnings Call Transcript ↗
CareDx (CDNA) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >